Genoscience Pharma is focused on developing innovative therapies that target cancer treatment by disrupting the energy supply of cancer cells, particularly through the modulation of lysosomal functions. The company has identified lysosomes as critical components in the survival and proliferation of cancer cells, making them a promising target for novel therapeutic strategies. Their approach involves creating small molecule drug candidates, such as GNS561 (ezurpimtrostat), which aim to deprive cancer cells of essential nutrients by interfering with lysosomal activity. This strategy is designed to enhance the effectiveness of existing treatments, such as immune checkpoint inhibitors, particularly in the context of hepatocellular carcinoma (HCC).

In addition to their work on lysosomal modulation, Genoscience Pharma is also exploring targeted degradation technologies through a collaboration with the Hebrew University of Jerusalem. This research focuses on PROTAC (Proteolysis Targeting Chimeras) technology, which has the potential to improve the potency and selectivity of small molecule drugs. By leveraging this technology, Genoscience Pharma aims to develop therapies that can effectively target and degrade specific proteins associated with cancer, thereby overcoming resistance to current treatments. This dual approach of lysosomal targeting and protein degradation represents a significant advancement in the quest for more effective cancer therapies.

France

Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. 
This is the first clinical stage company ever with unique lysosomotropic agents assessed in global clinical trials.

For more information, please visit our website, 
or call us +33 4 91 26 99 50.

Genoscience Pharma

Company Details